NCT01698333View on ClinicalTrials.gov

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

July 31, 2013

Conditions
Plaque Psoriasis
Interventions
DRUG

122-0551

Applied twice daily for 2 weeks

Trial Locations (3)

78759

DermResearch, Inc., Austin

92123

Therapeutics Clinical Research, San Diego

92801

Anaheim Clinical Trials, Anaheim

All Listed Sponsors
lead

Therapeutics, Inc.

INDUSTRY

NCT01698333 - Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression | Biotech Hunter | Biotech Hunter